Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182995 · ClinicalTrials.gov registry record · NA
Anticipating Decline and Providing Therapy
A NA study of Dementia and Cognitive Impairment, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
- 1
- Study location
NCT06182995: Completed NA study of Dementia and Cognitive Impairment, sponsored by Wake Forest University Health Sciences.
NCT06182995 is a NA study of Dementia and Cognitive Impairment that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 109 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06182995, a NA study of Dementia and Cognitive Impairment, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot feasibility study will be a randomized control trial of usual care following Intensive Care Unit (ICU) discharge compared to the Anticipating Decline and Providing Therapy (ADAPT) screening and support intervention. The trial aims to enroll 120 older adults (age 60 or older).
Primary Outcome
Number of participants in intervention arm who complete cognitive screening at 6 weeks
Conditions Studied
Interventions
- BEHAVIORAL Usual Care post-Intensive Care Unit (ICU)
- BEHAVIORAL Anticipating Decline and Providing Therapy (ADAPT)
Study Locations (1)
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What the finished NCT06182995 record still lists
NCT06182995 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Usual Care post-Intensive Care Unit (ICU) is the first listed.
NCT06182995 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06182995 about?
NCT06182995 is a clinical study titled "Anticipating Decline and Providing Therapy". This pilot feasibility study will be a randomized control trial of usual care following Intensive Care Unit (ICU) discharge compared to the Anticipating Decline and Providing Therapy (ADAPT) screening and support intervention. The trial aims to enroll 120 older adults (age 60 or older).
What is the current status of trial NCT06182995?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2024-03-08. Estimated completion is 2026-03-01.
What conditions does trial NCT06182995 study?
This clinical trial studies the following conditions: Dementia, Cognitive Impairment, Critical Illness, Cognitive Impairment, Mild, Post ICU Syndrome.
What interventions are being tested in trial NCT06182995?
The interventions under investigation include: Usual Care post-Intensive Care Unit (ICU) (BEHAVIORAL), Anticipating Decline and Providing Therapy (ADAPT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06182995?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06182995 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06182995's enrollment target sits among peer trials
109 114th of 199 higher than 86 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Caregiver as Navigator: Develop Skills Online (CAN-DO)
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Caregiver Bootcamp
RECRUITING · NA
-
Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision
RECRUITING · NA
-
Effect of Cognitive Empathy Training on Dementia Caregivers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI